153 related articles for article (PubMed ID: 27060276)
41. Pharmacokinetic-Pharmacodynamic Modeling of Enrofloxacin Against Escherichia coli in Broilers.
Sang K; Hao H; Huang L; Wang X; Yuan Z
Front Vet Sci; 2015; 2():80. PubMed ID: 26779495
[TBL] [Abstract][Full Text] [Related]
42. Postanitbiotic and sub-MIC effects of azithromycin and isepamicin against Staphylococcus aureus and Escherichia coli.
Fuentes F; Izquierdo J; Martín MM; Gomez-Lus ML; Prieto J
Antimicrob Agents Chemother; 1998 Feb; 42(2):414-8. PubMed ID: 9527796
[TBL] [Abstract][Full Text] [Related]
43. In vitro activities of daptomycin, vancomycin, and penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes.
Tyrrell KL; Citron DM; Warren YA; Fernandez HT; Merriam CV; Goldstein EJ
Antimicrob Agents Chemother; 2006 Aug; 50(8):2728-31. PubMed ID: 16870765
[TBL] [Abstract][Full Text] [Related]
44. Susceptibility to pleuromutilins in Brachyspira (Serpulina) hyodysenteriae.
Karlsson M; Gunnarsson A; Franklin A
Anim Health Res Rev; 2001 Jun; 2(1):59-65. PubMed ID: 11708748
[TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetic/pharmacodynamic relationship of marbofloxacin against Aeromonas hydrophila in Chinese soft-shelled turtles (Trionyx sinensis).
Shan Q; Zheng G; Liu S; Bai Y; Li L; Yin Y; Ma L; Zhu X
J Vet Pharmacol Ther; 2015 Dec; 38(6):537-42. PubMed ID: 25694049
[TBL] [Abstract][Full Text] [Related]
46. Bioassay-Guided Chromatographic Isolation and Identification of Antibacterial Compounds from Artemisia annua L. That Inhibit Clostridium perfringens Growth.
Ivarsen E; Fretté XC; Christensen KB; Christensen LP; Engberg RM; Grevsen K; Kjaer A
J AOAC Int; 2014; 97(5):1282-90. PubMed ID: 25902977
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetic/pharmacodynamic relationship of marbofloxacin against Pasteurella multocida in a tissue-cage model in yellow cattle.
Shan Q; Wang J; Yang F; Ding H; Liang C; Lv Z; Li Z; Zeng Z
J Vet Pharmacol Ther; 2014 Jun; 37(3):222-30. PubMed ID: 24033339
[TBL] [Abstract][Full Text] [Related]
48. In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
Andes D; Craig WA
Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987
[TBL] [Abstract][Full Text] [Related]
49. Optimal Regimens and Clinical Breakpoint of Avilamycin Against
Huang A; Luo X; Xu Z; Huang L; Wang X; Xie S; Pan Y; Fang S; Liu Z; Yuan Z; Hao H
Front Pharmacol; 2022; 13():769539. PubMed ID: 35281904
[No Abstract] [Full Text] [Related]
50. Mechanism of action of a novel recombinant peptide, MP1102, against Clostridium perfringens type C.
Zong L; Teng D; Wang X; Mao R; Yang N; Hao Y; Wang J
Appl Microbiol Biotechnol; 2016 Jun; 100(11):5045-57. PubMed ID: 26921181
[TBL] [Abstract][Full Text] [Related]
51. Association between gizzard lesions and increased caecal Clostridium perfringens counts in broiler chickens.
Novoa-Garrido M; Larsen S; Kaldhusdal M
Avian Pathol; 2006 Oct; 35(5):367-72. PubMed ID: 16990146
[TBL] [Abstract][Full Text] [Related]
52. Mycoplasma gallisepticum and Escherichia coli mixed infection model in broiler chickens for studying valnemulin pharmacokinetics.
Xiao X; Zhao DH; Yang X; Shi W; Deng H; Ma J; Zhang S; Liu YH
J Vet Pharmacol Ther; 2014 Feb; 37(1):99-102. PubMed ID: 23782411
[TBL] [Abstract][Full Text] [Related]
53. In vitro lecithinase activity and sensitivity to 22 antimicrobial agents of Clostridium perfringens isolated from necrotic enteritis of broiler chickens.
Kondo F
Res Vet Sci; 1988 Nov; 45(3):337-40. PubMed ID: 2905509
[TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetic-pharmacodynamic integration of moxifloxacin in rabbits after intravenous, intramuscular and oral administration.
Fernández-Varón E; Bovaira MJ; Espuny A; Escudero E; Vancraeynest D; Cárceles CM
J Vet Pharmacol Ther; 2005 Aug; 28(4):343-8. PubMed ID: 16050813
[TBL] [Abstract][Full Text] [Related]
55. The dose regimen formulation of tilmicosin against Lawsonia intracellularis in pigs by pharmacokinetic-pharmacodynamic (PK-PD) model.
Luo W; Qin H; Chen D; Wu M; Meng K; Zhang A; Pan Y; Qu W; Xie S
Microb Pathog; 2020 Oct; 147():104389. PubMed ID: 32707311
[TBL] [Abstract][Full Text] [Related]
56. A proposal of a pharmacokinetic/pharmacodynamic (PK/PD) index map for selecting an optimal PK/PD index from conventional indices (AUC/MIC, Cmax/MIC, and TAM) for antibiotics.
Kitamura Y; Yoshida K; Kusama M; Sugiyama Y
Drug Metab Pharmacokinet; 2014; 29(6):455-62. PubMed ID: 25008846
[TBL] [Abstract][Full Text] [Related]
57. Exogenous lysozyme influences Clostridium perfringens colonization and intestinal barrier function in broiler chickens.
Liu D; Guo Y; Wang Z; Yuan J
Avian Pathol; 2010 Feb; 39(1):17-24. PubMed ID: 20390532
[TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetics and pharmacodynamics of cefovecin in dogs.
Stegemann MR; Sherington J; Blanchflower S
J Vet Pharmacol Ther; 2006 Dec; 29(6):501-11. PubMed ID: 17083454
[TBL] [Abstract][Full Text] [Related]
59. Inhibitory effects of nisin against Clostridium perfringens food poisoning and nonfood-borne isolates.
Udompijitkul P; Paredes-Sabja D; Sarker MR
J Food Sci; 2012 Jan; 77(1):M51-6. PubMed ID: 22132724
[TBL] [Abstract][Full Text] [Related]
60. In vitro activity of chloropolysporin-C, a new glycopeptide-group antibiotic, on Clostridium perfringens isolates and its in vivo activity against C perfringens and other intestinal microflora of the caeca of broiler chickens.
Kondo F; Tateyama S
Res Vet Sci; 1990 Mar; 48(2):175-9. PubMed ID: 2333425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
